-+ 0.00%
-+ 0.00%
-+ 0.00%

Morgan Stanley Upgrades Quest Diagnostics to Overweight, Raises Price Target to $172

Benzinga·12/17/2024 11:15:48
Listen to the news
Morgan Stanley analyst Erin Wright upgrades Quest Diagnostics (NYSE:DGX) from Equal-Weight to Overweight and raises the price target from $145 to $172.